Form 4: Director Beeson Boosts XTNT Stake with DSU Award

Xtant Medical Holdings Director Jonn R. Beeson acquired 158,228 deferred stock units, increasing his beneficial ownership.

Summary

• Jonn R. Beeson, a Director of Xtant Medical Holdings, Inc. (XTNT), acquired 158,228 shares of common stock in the form of Deferred Stock Units (DSUs).
• The transaction occurred on November 15, 2025, with a deemed acquisition price of $0 per share.
• These DSUs are granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan.
• The 158,228 DSUs will vest on November 15, 2026, contingent upon Mr. Beeson remaining a director through that date.
• Settlement of the vested shares will be deferred to a later date as per the DSU award agreement.
• Following this transaction, Mr. Beeson directly beneficially owns 517,619 shares, which includes 465,570 shares issuable upon settlement of deferred stock units.
• He also indirectly beneficially owns 1,015,272 shares through The Platinum Legacy Trust, dated February 24, 2017, where he serves as Trustee.

Sentiment

Score: 7

Explanation: The acquisition of deferred stock units by a director is generally a positive signal, indicating continued commitment and alignment of interests with the company's long-term performance. It's a routine compensation event, not a major market-moving announcement, hence a moderately positive score.

Positives

• Director Jonn R. Beeson increased his direct beneficial ownership in Xtant Medical Holdings, Inc. by acquiring 158,228 Deferred Stock Units.
• The DSU award aligns the director's interests with long-term shareholder value, as vesting is conditioned on continued service.

Risks

• The vesting of the 158,228 Deferred Stock Units is conditioned upon Jonn R. Beeson remaining a director of Xtant Medical Holdings, Inc. through November 15, 2026.
• The settlement of vested DSU shares is deferred to a later date, meaning the actual receipt of shares is not immediate upon vesting.

Future Outlook

The filing indicates a future vesting event on November 15, 2026, for the newly granted Deferred Stock Units, contingent on the director's continued service. The actual settlement of these vested shares will occur at a later, unspecified date.

Industry Context

This Form 4 filing reports a routine insider transaction (DSU grant) for a director of a medical device company. Such grants are common compensation practices in the industry to align executive and director interests with long-term company performance and retention. It does not provide broader industry trends or competitive analysis.

Comparison to Industry Standards

• Deferred Stock Unit (DSU) awards are a standard component of director compensation packages across various industries, including medical technology, to promote long-term commitment and align interests with shareholders.
• The vesting schedule, conditioned on continued service, is typical for such equity awards, similar to practices at companies like Medtronic, Stryker, or Zimmer Biomet, which also utilize equity-based compensation for their directors.
• The $0 acquisition price is standard for DSU grants, as they represent a right to receive shares in the future, not an immediate purchase.

Corporate Governance

Related Party Transactions

• Jonn R. Beeson indirectly owns 1,015,272 shares through The Platinum Legacy Trust, dated February 24, 2017, where he serves as Trustee.

Stakeholder Impact

• Shareholders: The DSU award aligns the director's long-term interests with shareholders, potentially fostering more stable governance and strategic decisions.
• Employees: No direct impact mentioned, but a strong board can indirectly benefit all employees through sound strategic direction.

Next Steps

• Vesting of 158,228 Deferred Stock Units on November 15, 2026, subject to continued directorship.
• Settlement of vested DSU shares at a later, unspecified date.

Key Dates

Recommendation

This Form 4 filing reports a routine equity compensation grant to a director, which is a standard practice to align interests. It does not contain information that would fundamentally alter the investment thesis for Xtant Medical Holdings, Inc. Therefore, a 'hold' recommendation is appropriate, as the filing provides no new catalysts for a 'buy' or 'sell' decision, but rather confirms ongoing corporate governance practices.

Keywords

Xtant Medical Holdings, XTNT, Form 4, Insider Transaction, Deferred Stock Units, DSU, Equity Incentive Plan, Director Ownership, Beneficial Ownership, Stock Award